Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis

Stem Cells

Volumn 29, Issue 10, 2011, Pages 1549-1558

  Duijvestein, Marjolijn ^a   Wildenberg, Manon E ^a,b   Welling, Mick M ^a   Hennink, Simone ^a   Molendijk, Ilse ^a   Van Zuylen, Vanessa L ^a   Bosse, Tjalling ^a   Vos, Anne Christine W ^a   De Jonge Muller, Eveline S M ^a   Roelofs, Helene ^a   Van Der Weerd, Louise ^a   Verspaget, Hein W ^a   Fibbe, Willem E ^a   Te Velde, Anje A ^b   Van Den Brink, Gijs R ^a,b   Hommes, Daniel W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; Experimental mouse model; Mesenchymal stem cell; Mesenchymal stromal cells

Indexed keywords

AMYLOID A PROTEIN; DEXTRAN SULFATE; GAMMA INTERFERON; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL MIGRATION; COLITIS; COLON; CONTROLLED STUDY; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PREMEDICATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STROMA CELL; SURVIVAL RATE;

ANIMALS; BODY WEIGHT; CELL DIFFERENTIATION; CELL MOVEMENT; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; INTESTINAL MUCOSA; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SERUM AMYLOID A PROTEIN; TRINITROBENZENESULFONIC ACID;

ANIMALIA; MUS;

EID: 80053221596     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.698     Document Type: Article

References (41)

1. Da Silva ML, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204-2213. (Pubitemid 43960310)
2. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-48. (Pubitemid 34059216)
3. Glennie S, Soeiro I, Dyson PJ et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-2827. (Pubitemid 40446275)
4. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-3729. (Pubitemid 36857965)
5. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-398. (Pubitemid 44464808)
6. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-150. (Pubitemid 351181031)
7. Ryan JM, Barry F, Murphy JM et al. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007;149:353-363. (Pubitemid 47063057)
8. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621. (Pubitemid 38745993)
9. Polchert D, Sobinsky J, Douglas G et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008;38:1745-1755.
10. Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther 2008;8:1417-1423.
11. Ball LM, Bernardo ME, Roelofs H et al. Co-transplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood 2007;110:2764-2767.
12. Kebriaei P, Isola L, Bahceci E et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009;15:804-811.
13. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441. (Pubitemid 38586721)
14. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of severe acute graft-versus-host disease. Blood 2006;108:2918.
15. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397. (Pubitemid 43847148)
16. Duijvestein M, Vos AC, Roelofs H et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study. Gut 2010;59:1662-1669.
17. Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: Correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005;288:G1328-G1338. (Pubitemid 40741088)
18. Camoglio L, te Velde AA, de BA et al. Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur J Immunol 2000;30:1486-1495. (Pubitemid 30311980)
19. van Hensbergen Y, Schipper LF, Brand A et al. Ex vivo culture of human CD34+ cord blood cells with thrombopoietin (TPO) accelerates platelet engraftment in a NOD/SCID mouse model. Exp Hematol 2006;34:943-950.
20. Welling M, Feitsma HI, Blok D et al. A new 99mTc labelling method for leucocytes: In vitro and in vivo comparison with 99mTc-HMPAO. Q J Nucl Med 1995;39:89-98.
21. Battke F. Mayday - Integrative analytics for expression data. 2010.
22. Dominici M, Le BK, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317. (Pubitemid 44269669)
23. Rameshwar P. IFNgamma and B7-H1 in the immunology of mesenchymal stem cells. Cell Res 2008;18:805-806.
24. Romieu-Mourez R, Francois M, Boivin MN et al. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, And Cell Density J Immunol 2007;179:1549-1558.
25. Stagg J, Pommey S, Eliopoulos N et al. Interferon-gamma-stimulated marrow stromal cells: A new type of nonhematopoietic antigen-presenting cell. Blood 2006;107:2570-2577. (Pubitemid 43348704)
26. Alex P, Zachos NC, Nguyen T et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009;15:341-352.
27. Ito R, Kita M, Shin-Ya M et al. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 2008;377:12-16.
28. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000;19:51-62. (Pubitemid 30146942)
29. Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Protoc Immunol 2002;Chapter 15:Unit 15.19.
30. Zhang Z, Zheng M, Bindas J et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-388.
31. Chapel A, Bertho JM, Bensidhoum M et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003;5:1028-1038. (Pubitemid 40310427)
32. Garcia-Olmo D, Garcia-Arranz M, Herreros D et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48:1416-1423. (Pubitemid 40933870)
33. Opitz CA, Litzenburger UM, Lutz C et al, Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009;27:909-919.
34. English K, Barry FP, Field-Corbett CP et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007;110:91-100. (Pubitemid 46830943)
35. Gonzalez-Rey E, Anderson P, Gonzalez MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929-939.
36. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009;136:978-989.
37. Zhang Q, Shi S, Liu Y et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009;183:7787-7798.
38. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Treatment of experimental arthritis by inducing immune tolerance with human adiposederived mesenchymal stem cells. Arthritis Rheum 2009;60:1006-1019.
39. Zhang J, Li Y, Chen J et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005;195:16-26. (Pubitemid 41116810)
40. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001. (Pubitemid 36857986)
41. Ko IK, Kim BG, Awadallah A et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther 2010;18:1365-1372.